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Background: Patients with early-stage non–small-cell lung carci-
noma (NSCLC) may benefit from treatments based on more accurate 
prognosis. A 15-gene prognostic classifier for NSCLC was identified 
from mRNA expression profiling of tumor samples from the NCIC 
CTG JBR.10 trial. In this study, we assessed its value in an indepen-
dent set of cases.
Methods: Expression profiling was performed on RNA from fro-
zen, resected tumor tissues corresponding to 181 stage I and II 
NSCLC cases collected at University Health Network (UHN181). 
Kaplan–Meier methodology was used to estimate 5-year overall 
survival probabilities, and the prognostic effect of the classifier 
was assessed using the log-rank test. A Cox proportional hazards 
model evaluated the signature’s effect adjusting for clinical prog-
nostic factors.
Results: Expression data of the 15-gene classifier stratified 
UHN181 cases into high- and low-risk subgroups with significantly 
different overall survival (hazard ratio [HR] = 1.92; 95% confi-
dence interval [CI], 1.15–3.23; p = 0.012). In a subgroup analysis, 
this classifier predicted survival in 127 stage I patients (HR = 2.17; 
95% CI, 1.12–4.20; p = 0.018) and the smaller subgroup of 48 
stage IA patients (HR = 5.61; 95% CI, 1.19–26.45; p = 0.014). The 
signature was prognostic for both adenocarcinoma and squamous 
cell carcinoma cases (HR = 1.76, p = 0.058; HR = 4.19, p = 0.045, 
respectively).
Conclusion: The prognostic accuracy of a 15-gene classifier was 
validated in an independent cohort of 181 early-stage NSCLC sam-
ples including stage IA cases and in different NSCLC histologic 
subtypes.
Key Words: Non–small-cell lung carcinoma, Prognosis, Biomarkers, 
Adenocarcinoma, Squamous cell carcinoma.
(J Thorac Oncol. 2014;9: 59–64)
Lung cancer is the leading cause of cancer death and non–small-cell lung carcinoma (NSCLC) accounts for approxi-
mately 85% of all cases.1 The majority of NSCLC patients are 
diagnosed in advanced or metastatic stages, which largely are 
inoperable.2 Early stage I and II NSCLC cases are potentially 
curable by complete surgical resection,3 and survival can be 
improved with adjuvant chemotherapy, mainly in stage II4–6 
and possibly in stage I patients with 4 cm diameter or higher.7–9 
Investigators have continued to seek prognostic markers and 
markers that are predictive of survival benefit from adjuvant 
chemotherapy, as it is recognized that these could form the 
basis for developing personalized approaches to improve the 
survival of early-stage NSCLC patients.10,11 Currently, stage II 
patients are treated with adjuvant chemotherapy; although the 
benefit to the group as a whole has been established,12–14 there 
are patients with inherently good prognosis who potentially 
could be spared the morbidity associated with adjuvant chemo-
therapy. Stage I patients could benefit the most from a strong 
prognostic marker, as the survival of patients with poor prog-
nosis could potentially be improved by adjuvant chemotherapy.
Our group had developed an mRNA-based classifier com-
prising 15 genes (Table 4)15 by expression profiling snap-frozen, 
tumor samples collected in the NCIC CTG JBR.10 trial.14 The 
accuracy of this classifier as a prognostic marker was established 
initially by in silico validation in four large public NSCLC 
expression datasets. In this study, we further tested the perfor-
mance of this 15-gene classifier in an independent cohort of 181 
snap-frozen samples from early-stage NSCLC patients collected 
at University Health Network (UHN) who did not receive any 
adjuvant therapy. As a validation study, the same assay platform 
(Affymetrix) was used here as in the discovery study.15
MATERIALS AND METHODS
NSCLC Tumor Samples and Patients
Snap-frozen tumor samples from NSCLC patients who 
underwent surgical resection at the UHN during 1996–2005 
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were retrieved from the UHN tumor bank, using a protocol 
approved by the UHN Research Ethics Board. Patient tumor 
stage and histological classification were obtained from elec-
tronic patient records. On the basis of the tumor size infor-
mation, some tumor stages were adjusted accordingly to the 
7th edition tumor, node, metastasis (TNM) criteria. Exclusion 
criteria included patients with stage III or IV disease or those 
received any form of adjuvant therapy and samples with tumor 
cellularity of less than 20%. Histology and tumor cellularity 
were assessed by review of the representative H&E section of 
frozen tumor samples used for RNA extraction. During this 
assessment, the tumor histological type was recorded. Cases 
with significant discrepancy as compared with the original 
diagnosis were reviewed further to provide the final histologi-
cal diagnosis. Approximately 210 cases meeting these crite-
ria were identified initially and total RNA was extracted as 
described previously.15 In brief, frozen tissue fragments were 
homogenized and total RNA was isolated using the RNAZol 
(Invitrogen, Carlsbad, CA). Cases with low RNA yield or 
poor RNA integrity, as defined by RIN scores less than 8.0 by 
BioAnalyzer (Agilent Technologies, Santa Clara, CA), were 
excluded. A total of 181 RNA samples were processed by 
expression profiling using Affymetrix U133 2.0 Plus arrays 
(Princess Margaret Genomics Centre, Toronto, Ontario, 
Canada).
Data Analysis
Microarray data were normalized using robust multi-
array averaging and deposited with GEO (GSE50081). The 
expression values for the 15 genes comprising the classifier 
were extracted using methods described previously (Table 4),15 
and prognostic accuracy was tested in the entire set of 181 
samples, and by stage and histologic subtype. As outlined pre-
viously,15 a risk score was calculated using a weighted sum 
of four principal components derived from the expression 
values of the 15 probe sets. This risk score was then dichot-
omized at the median of −0.1 with high-risk patients being 
those patients whose risk score was greater than this value 
and low risk otherwise. Overall survival up to 5 years was 
used as the endpoint of interest. Patients with more than 5 
years follow-up were censored at 5 years as deaths occur-
ring later than 5 years were not likely to be lung cancer 
related. The survival probabilities were calculated using 
the Kaplan–Meier method. Differences in survival curves 
were assessed using the log-rank test. Hazard ratios (HRs) 
and 95% confidence intervals (CI) were generated using 
a Cox proportional hazards model. Multivariable analyses 
adjusted the model for clinical factors such as age, sex, 
stage, and histology. Schoenfeld residuals for all models 
were assessed to ensure the proportionality assumption 
was met. All analyses were performed using the survival 
package (version 2.36–5) in the open-source software R 
version 2.12.16 A two-sided p value of 0.05 was used to 
assess statistical significance.
RESULTS
Patient Cohorts
The primary objective of this study was to validate 
the prognostic accuracy of the 15-gene classifier in a larger 
cohort of early-stage NSCLC cases than in our previous 
study (Table 1).15 Although the JBR.10 cohort included 
only stage IB and stage II patients, the UHN181 cohort 
included all stage I and stage II patients, and specifically, 
48 stage IA patients. As a result, the ratio of stage I:II in 
UHN181 (70:30) was higher than in the JBR.10 cohort 
(55:45). Sex was biased toward males in both UHN181 
(54%) and JBR.10 (71%). The most prevalent NSCLC his-
tology in both cohorts was adenocarcinoma, 71 and 52%, 
respectively, whereas the representation of (SqCC) was 
24 and 42%. Sixty-three deaths occurred within 5 years. 
Of the 118 patients alive, 81 patients (69%) had complete 
follow-up to 5 years and 15 patients (13%) had follow-up 
less than 3 years.
Prognostic Performance of the JBR.10 Signature
Consistent with early-stage NSCLC patients, stage 
was a prognostic marker in the UHN181 patients although 
it was not statistically significant in this cohort (Fig. 1A). 
In comparison, the 15-gene classifier when applied to the 
entire UHN181 cohort was able to classify patients into low- 
and high-risk survival groups with statistical significance 
on both univariable and multivariable analyses (Fig. 1B 
and Table 2, multivariable-adjusted HR = 1.95; 95% CI, 
1.15–3.30; Wald p = 0.013). This result was comparable 
TABLE 1.  Comparison of Demographics between UHN181 
and JBR.10 Cohorts
Variable UHN181 (n = 181) JBR.10 (n = 62)a
Age
  Median age (range) 69.7 (40.2–87.9) 61 (35–77)
  <65 years 59 (33%) 43 (69%)
  ≥65 years 122 (67%) 19 (31%)
Sex
  Female 83 (46%) 18 (29%)
  Male 98 (54%) 44 (71%)
Histology
  Adenocarcinoma 128 (71%) 32 (52%)
  Squamous cell 
carcinoma
43 (24%) 26 (42%)
  Othersb 10 (6%) 4 (6%)
Stage
  IA 48 (27%) 0
  IB 79 (44%) 34 (55%)
  IIA 9 (5%) 28 (45%)
  IIB 45 (25%) 0
15-gene signature
  Low risk 87 (48%) 29 (47%)
  High risk 94 (52%) 33 (53%)
aIncluded only patients who were treated by surgery alone.
bInclude large cell and adeno-squamous carcinoma.
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with the range of HR values observed in our previous vali-
dation study15 using four published NSCLC microarray 
datasets as external validation (HR = 2.26, 2.27, 1.96, and 
3.57 for datasets corresponding to Director’s Challenge,17 
Netherlands Cancer Institute,18 Duke University,19 and 
University of Michigan SqCC,20 respectively). The prog-
nostic strength of this classifier was independent of histol-
ogy (Fig. 2, A–D).
The 15-gene classifier originally was trained and vali-
dated on only stage IB and stage II patients together, and thus 
its performance for stage IA patients was unknown. When 
tested in the 48 stage 1A patient subgroup of the UHN181 
cohort, the signature classified 27 patients as low-risk group 
with a 92% 5-year survival rate, and 21 as high-risk with a 
5-year survival rate of 61% (HR = 5.61; 95% CI, 1.19–26.45; 
Wald p = 0.014) (Fig. 2E and Table 3). However, the ability 
to predict high- or low-risk groups among stage IB patients 
alone did not achieve statistical significance (HR = 1.43; 95% 
CI, 0.68–2.99; Wald p = 0.34; Fig. 2F).
DISCUSSION
This study was designed to test prospectively in a 
blinded manner, the prognostic value of the 15-gene signa-
ture in a new cohort of banked tumor samples representing 
complete resections from stage I and II NSCLC patients who 
received no adjuvant therapy. As a validation study, we chose 
to use the same type of microarray platform but with the sam-
ple processing and hybridization performed in an independent 
laboratory and more than 5 years after the original study. The 
results confirmed the prognostic value of the 15-gene signa-
ture for stage I and II patients together and showed that its 
prognostic value was independent of histology. We also have 
demonstrated its ability to identity high-risk stage I patients. 
The signature was unable to predict survival in stage IB alone, 
or combined stage IB and II patients, which we presently can 
only attribute to cohort variability. However, this study reveals 
that the signature was able to stratify stage IA patient sub-
groups with significantly different 5-year survival outcomes 
(92% for low risk versus 61% for high risk). This may have 
considerable clinical relevance since at this time stage IA 
patients are not offered adjuvant chemotherapy.
The 15-gene expression prognostic signature was devel-
oped from the microarray analysis of snap-frozen tumor sam-
ples collected from patients who participated in the JBR.10 
adjuvant chemotherapy trial.14 This was one of the pivotal 
trials that established adjuvant chemotherapy as beneficial 
in improving the survival of early-stage NSCLC patients. 
Among 482 patients who were randomized, 169 patients 
had snap-frozen tumor samples collected prospectively and 
banked as part of the trial protocol. Expression microarray 
profiling was conducted in samples of 133 patients, 62 in the 
observation arm, and 71 in the adjuvant chemotherapy arm. 
The prognostic gene signature was identified in the observa-
tion (surgery only) cohort, using the Maximizing R Square 
(MARSA) algorithm.15 The signature was able to classify 
the 62 patients into 31 low-risk and 31 high-risk individu-
als, with significantly different survival outcomes (adjusted 
TABLE 2.  Adjusted Prognostic Value of the 15-Gene 
Signature in Presence of Other Clinical-Pathological Factors
Hazard Ratio 95% CI p
Gene signature
  Low Risk 1.00 — — —
  High Risk 1.95 1.15 3.30 0.013
Sex
  Female 1.00 — — —
  Male 2.02 1.17 3.47 0.011
Age
  <65 1.00 — — —
  ≥65 1.56 0.88 2.75 0.13
Histology
  Adenocarcinoma 0.72 0.41 1.25 0.25
  Other 1.00 — — —
Stage
  I (n = 127) 1.00 — — —
  II (n = 54) 1.72 1.02 2.90 0.042
CI, confidence interval.
FIGURE 1.  Kaplan–Meier survival 
curves for all 181 patients. A, Stage 
I versus stage II patients. B, Low risk 
versus high risk. HR, hazard ratio; 
CI, confidence interval; OS, overall 
survival.
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HR = 18.00; 95% CI, 5.78–56.05; p = 0.001). The prognostic 
signature validated separately in four independent microar-
ray data sets (a total of 356 stage-IB/II NSCLC patients who 
had not receive adjuvant treatment), and in an additional 19 
JBR.10 observation only patients by real-time quantitative 
polymerase chain reaction. Most importantly, the signature 
also seemed to be predictive of improved survival after adju-
vant chemotherapy in JBR.10 high-risk patients (HR che-
motherapy versus observation, 0.33; 95% CI, 0.17–0.63; 
p = 0.0005), but not in low-risk patients where chemotherapy 
FIGURE 2.  Kaplan–Meier survival curves for patient subgroups. A, Gene signature in stage I patients. B, Gene signature in 
stage II patients. C, Gene signature in AdC patients. D, Gene signature in SqCC patients. E, Gene signature in stage IA patients. 
F, Gene signature in stage IB patients. HR, hazard ratio; CI, confidence interval; OS, overall survival; AdC, adenocarcinoma; 
SqCC, squamous cell carcinoma.
TABLE 3.  Summary of Survival Estimates at 5 Years for Patient Subgroups in Different Stages
Cohort Variable Groups within Variable Survival at 5 yr, % Hazard Ratio Log-Rank p
All Stage I 65 1.00 0.11
II 54 1.52
All Stage IA 78 1.00 0.039
IB 58 2.12
II 54 2.53
Stage I (n = 127) 15 g sign Low risk 77 1.00 0.018
High risk 54 2.17
Stage IA (n = 48) 15 g sign Low risk 92 1.00 0.014
High risk 61 5.61
Stage IB (n = 79) 15 g sign Low risk 65 1.00 0.34
High risk 52 1.43
Stage II (n = 54) 15 g sign Low risk 61 1.00 0.27
High risk 47 1.61
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seemed to be detrimental (HR = 3.67; 95% CI, 1.22–11.06; 
p = 0.0133; interaction p = 0.001). However, this could not 
be validated as microarray datasets from randomized stud-
ies with treated and untreated control arms were not avail-
able. Nevertheless, Tang et al.21 has recently identified a 
12-gene signature that was predictive of responsiveness to 
chemotherapy in two patient cohorts, the JBR.1015 and the 
UT Lung SPORE datasets, and made public their dataset. 
We have determined that the 15-gene signature could also 
predict response to ACT in the UT Lung SPORE dataset, 
particularly for stage I patients, although interaction of risk 
group and ACT on survival was not significant, for stage I 
alone, or combined with stage II (Supplementary Figure S1, 
Supplementary Digital Content, http://links.lww.com/JTO/
A495). This also affirms the concept that there can be mul-
tiple classifiers that predict clinical outcomes from genomic 
datasets despite being inherently different in their gene com-
position.22 To our best knowledge, no study has yet validated 
the impact of applying a prognostic and/or predictive clas-
sifier to guide treatment decisions for NSCLC patients with 
regard to receiving adjuvant therapy and evaluate resultant 
clinical outcomes. Although an accurate classifier that pre-
dicts responsiveness to therapy ideally should provide the 
best guidance to help individualize treatment for patients, it 
remains possible that a test enabling better prognosis alone 
and partnered with a specific treatment, whether adjuvant 
chemotherapy or some other treatment, potentially also could 
provide clinical utility.
More than 30 prognostic gene signatures have been 
reported by various investigators,10 but to our knowledge, 
only one signature23 has become available as a clinical test 
(Pervenio RS test, Life Technologies, Inc., Grand Island, NY). 
This 14-gene signature was developed using real-time quan-
titative polymerase chain reaction directly on RNA isolated 
from FFPE tumor samples of 361 stage I–IV nonsquamous 
NSCLC patients resected at the University of California at 
San Francisco, with validation in two independent cohorts of 
nonsquamous NSCLC patients: 433 patients with stage I (285 
stage IA and 135 stage IB) nonsquamous NSCLC resected in 
a U.S. institution, and 1006 patients with stage I–III nonsqua-
mous NSCLC resected in multiple institutions in China. In the 
U.S. validation cohort, the adjusted HR for the signature by 
Kratz et al. was 2.04 (95% CI, 1.28–3.26; p = 0.0016), which 
is similar to the HR achieved by the 15-gene signature studied 
here. However, the Kratz et al.23 signature did not demonstrate 
ability to predict for adjuvant chemotherapy benefit, as simi-
lar HRs were generated in both training cohorts of patients 
who received or did not receive adjuvant chemotherapy. In 
contrast, the 15-gene signature demonstrated potential for 
predicting responsiveness to chemotherapy15 although these 
aspects have not been validated yet in an independent cohort. 
Finally, although the signature by Kratz et al. was developed 
specifically for nonsquamous NSCLC, the 15-gene signature 
can identify prognostic subgroups for both SqCC and adeno-
carcinoma patients. Therefore, the 15-gene signature seems to 
have the most promising potential among all published sig-
natures to identify patients who may or may not benefit from 
adjuvant chemotherapy among the broad spectrum of early-
stage NSCLC cases, independent of stage and histology.
ACKNOWLEDGMENTS
Research funding for this study was provided by Med 
BioGene Inc. and research grants from the Canadian Institutes 
of Health Research (CIHR) Proof of Principle Program 
(grant No. 86173), the Canadian Cancer Society Research 
Institute (grant No. 020527), partially by the Ontario Ministry 
of Health and Long Term Care, and the Princess Margaret 
Hospital Foundation.
REFERENCES
 1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J 
Clin 2010;60:277–300.
 2. Goldstraw P, Crowley J, Chansky K, et al.; International Association for 
the Study of Lung Cancer International Staging Committee; Participating 
Institutions. The IASLC Lung Cancer Staging Project: proposals for the 
revision of the TNM stage groupings in the forthcoming (seventh) edi-
tion of the TNM Classification of malignant tumours. J Thorac Oncol 
2007;2:706–714.
 3. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for 
early stage lung cancer: an 11-year experience with 975 patients. Cancer 
2009;115:5218–5227.
 4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, 
Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative 
Group. Cisplatin-based adjuvant chemotherapy in patients with completely 
resected non-small-cell lung cancer. N Engl J Med 2004;350:351–360.
 5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus 
cisplatin versus observation in patients with completely resected stage 
IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International 
Trialist Association [ANITA]): a randomised controlled trial. Lancet 
Oncol 2006;7:719–727.
 6. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing 
cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemother-
apy-naive patients with advanced-stage non-small-cell lung cancer. J Clin 
Oncol 2008;26:3543–3551.
TABLE 4.  Genes and Original Probe Sets Comprising the 
15-Gene Signature
Gene Symbol Probe Set Gene Title
ATP1B1 201243_s_at ATPase, Na+/K+ transporting, β1 polypeptide
TRIM14 203147_s_at Tripartite motif-containing 14
FAM64A 221591_s_at Family with sequence similarity 64, member A
FOSL2 218881_s_at FOS-like antigen 2
HEXIM1 202814_s_at Hexamethylene bis-acetamide inducible 1
MB 204179_at Myoglobin
L1CAM 204584_at L1 cell adhesion molecule
UMPS 202707_at Uridine monophosphate synthetase
EDN3 208399_s_at Endothelin 3
STMN2 203001_s_at Stathmin-like 2
MYT1L 210016_at Myelin transcription factor 1-like
IKBKAP 202490_at Inhibitor of κ-light polypeptide gene enhancer 
in B-cells, kinase complex–associated 
protein
MLANA 206426_at Melan-A
MDM2 205386_s_at Mdm2, transformed 3T3 cell double minute 2
ZNF236 219171_s_at Zinc finger protein 236
64 Copyright © 2013 by the International Association for the Study of Lung Cancer
Der et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014
 7. Pignon JP, Tribodet H, Scagliotti GV, et al.; LACE Collaborative Group. 
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE 
Collaborative Group. J Clin Oncol 2008;26:3552–3559.
 8. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel 
plus carboplatin compared with observation in stage IB non-small-cell 
lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, 
Radiation Therapy Oncology Group, and North Central Cancer Treatment 
Group Study Groups. J Clin Oncol 2008;26:5043–5051.
 9. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of 
vinorelbine plus cisplatin compared with observation in completely 
resected stage IB and II non-small-cell lung cancer: updated survival 
analysis of JBR-10. J Clin Oncol 2010;28:29–34.
 10. Zhu CQ, Pintilie M, John T, et al. Understanding prognostic gene 
 expression signatures in lung cancer. Clin Lung Cancer 2009;10:331–340.
 11. Subramanian J, Simon R. Gene expression-based prognostic signatures in 
lung cancer: ready for clinical use? J Natl Cancer Inst 2010;102:464–474.
 12. Pisters KM, Evans WK, Azzoli CG, et al.; Cancer Care Ontario; American 
Society of Clinical Oncology. Cancer Care Ontario and American Society 
of Clinical Oncology adjuvant chemotherapy and adjuvant radiation 
therapy for stages I-IIIA resectable non small-cell lung cancer guideline. 
J Clin Oncol 2007;25:5506–5518.
 13. Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant chemotherapy for 
early-stage non-small cell lung cancer. Chest 2005;128:2933–2943.
 14. Winton T, Livingston R, Johnson D, et al.; National Cancer Institute of 
Canada Clinical Trials Group; National Cancer Institute of the United 
States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin 
vs. observation in resected non-small-cell lung cancer. N Engl J Med 
2005;352:2589–2597.
 15. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene sig-
nature for adjuvant chemotherapy in resected non-small-cell lung cancer. 
J Clin Oncol 2010;28:4417–4424.
 16. R Development Core Team (2010). R: A Language and Environment 
for Statistical Computing. Vienna, Austria: R Foundation for Statistical 
Computing. ISBN 3-900051-07-0. Available at: http://www.R-project.org/
 17. Shedden K, Taylor JM, Enkemann SA et al. Gene expression-based sur-
vival prediction in lung adenocarcinoma: a multi-site, blinded validation 
study. Nat Med. 2008;14:822–827.
 18. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 
72-gene prognostic profile for early-stage non-small-cell lung cancer. 
Clin Cancer Res 2009;15:284–290.
 19. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine 
prognosis in early-stage non-small-cell lung cancer. N Engl J Med 
2006;355:570–580.
 20. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting 
prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 
2006;66:7466–7472.
 21. Tang H, Xiao G, Behrens C, et al. A 12-gene set predicts survival benefits 
from adjuvant chemotherapy in non-small cell lung cancer patients. Clin 
Cancer Res 2013;19:1577–1586.
 22. Boutros PC, Lau SK, Pintilie M, et al. Prognostic gene signa-
tures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 
2009;106:2824–2828.
 23. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay 
to predict survival in resected non-squamous, non-small-cell lung 
cancer: development and international validation studies. Lancet 
2012;379:823–832.
